Methotrexate + Ibrutinib + Temozolomide
Phase 2UNKNOWN 1 views this week 0 watching💤 Quiet
Interest: 31/100
31
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Central Nervous System Lymphoma
Conditions
Primary Central Nervous System Lymphoma, PCNSL, Non Hodgkin Lymphoma
Trial Timeline
Oct 10, 2020 → Jun 1, 2024
NCT ID
NCT04514393About Methotrexate + Ibrutinib + Temozolomide
Methotrexate + Ibrutinib + Temozolomide is a phase 2 stage product being developed by Sun Pharmaceutical for Primary Central Nervous System Lymphoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT04514393. Target conditions include Primary Central Nervous System Lymphoma, PCNSL, Non Hodgkin Lymphoma.
What happened to similar drugs?
20 of 20 similar drugs in Primary Central Nervous System Lymphoma were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
12
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04514393 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Primary Central Nervous System Lymphoma